key: cord-0785167-uwe5q80q
authors: Ayala Gutiérrez, María del Mar; Rubio-Rivas, Manuel; Romero Gómez, Carlos; Montero Sáez, Abelardo; Pérez de Pedro, Iván; Homs, Narcís; Ayuso García, Blanca; Cuenca Carvajal, Carmen; Arnalich Fernández, Francisco; Beato Pérez, José Luis; Vargas Núñez, Juan Antonio; Letona Giménez, Laura; Suárez Fernández, Carmen; Méndez Bailón, Manuel; Tuñón de Almeida, Carlota; González Moraleja, Julio; de Guzmán García-Monge, Mayte; Helguera Amezua, Cristina; Fidalgo Montero, María del Pilar; Giner Galvañ, Vicente; Gil Sánchez, Ricardo; Collado Sáenz, Jorge; Boixeda, Ramon; Ramos Rincón, José Manuel; Gómez Huelgas, Ricardo
title: Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry
date: 2021-04-23
journal: J Clin Med
DOI: 10.3390/jcm10091844
sha: aa163c9785613676c18e1cfc0b5c9112f350e010
doc_id: 785167
cord_uid: uwe5q80q

(1) Objectives: To describe the clinical characteristics and clinical course of hospitalized patients with COVID-19 and autoimmune diseases (ADs) compared to the general population. (2) Methods: We used information available in the nationwide Spanish SEMI-COVID-19 Registry, which retrospectively compiles data from the first admission of adult patients with COVID-19. We selected all patients with ADs included in the registry and compared them to the remaining patients. The primary outcome was all-cause mortality during admission, readmission, and subsequent admissions, and secondary outcomes were a composite outcome including the need for intensive care unit (ICU) admission, invasive and non-invasive mechanical ventilation (MV), or death, as well as in-hospital complications. (3) Results: A total of 13,940 patients diagnosed with COVID-19 were included, of which 362 (2.6%) had an AD. Patients with ADs were older, more likely to be female, and had greater comorbidity. On the multivariate logistic regression analysis, which involved the inverse propensity score weighting method, AD as a whole was not associated with an increased risk of any of the outcome variables. Habitual treatment with corticosteroids (CSs), age, Barthel Index score, and comorbidity were associated with poor outcomes. Biological disease-modifying anti-rheumatic drugs (bDMARDs) were associated with a decrease in mortality in patients with AD. (4) Conclusions: The analysis of the SEMI-COVID-19 Registry shows that ADs do not lead to a different prognosis, measured by mortality, complications, or the composite outcome. Considered individually, it seems that some diseases entail a different prognosis than that of the general population. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects.

The novel coronavirus 2019 disease (COVID- 19) pandemic has spread throughout the world. Spain is one of the most affected countries in Europe, with more than 3,153,000 cumulative cases [1] .

The infection has a more severe course in elderly men or those with comorbidities [2, 3] . In the case of patients with autoimmune diseases (ADs), questions have been raised about the true susceptibility to SARS-CoV-2 infection and the course of the AD after infection. In general, the underlying dysfunction of their immune system and the immunosuppressive/immunoregulatory treatments (ISTs) they receive mean that some patients with ADs are at greater risk of infection [4, 5] . Different studies have observed a frequency of COVID-19 in these patients that is higher than that of the general population [6] [7] [8] , as well as a worse prognosis in terms of the need for mechanical ventilation (MV) or admission to intensive care units (ICUs) [9] . In others, however, the frequency of COVID-19 [10] [11] [12] [13] [14] and its prognosis were similar to patients without ADs [13, [15] [16] [17] [18] [19] . It has been suggested that patients with ADs could have adopted stricter and earlier self-protection and social distancing measures than the general population [12, 20] .

On the other hand, antimalarials, which are common in the treatment of ADs, have in vitro antiviral effects [21] , although no protective effect has been demonstrated [9, 12, 22, 23] . In the inflammatory phase of COVID-19, ISTs could protect patients with ADs who usually receive them from the onset of a cytokine storm, which is associated with a poor prognosis [14, 15, 24] . Finally, some ADs have basal characteristics that could influence the course of COVID-19, both positively (overexpression of interferon alpha [25] ) and negatively (lymphopenia [26] or epigenetic dysregulation [27] ).

The Spanish Society of Internal Medicine (SEMI) has created a registry of patients hospitalized due to COVID-19 in Spain. This registry makes it possible to compare the sociodemographic and clinical characteristics and the clinical course of patients with and without ADs in order to establish whether differences exist between them.

We have used the information available in the Spanish nationwide SEMI-COVID- 19 Registry, which retrospectively compiles data from the first admission of patients ≥ 18 years of age with COVID-19, confirmed microbiologically by a reverse transcription polymerase chain reaction (RT-PCR) test of a nasopharyngeal swab sample, sputum specimen, or bronchoalveolar lavage. This registry collects sociodemographic data, previous medical history, routine treatment (including CS, antimalarials, conventional or targeted disease-modifying anti-rheumatic drugs (cs/tsDMARDs), and bDMARDs), clinical presentation, clinical condition (including the degree of functional dependence, as evaluated by the Barthel Index [28] , and the presence of comorbidities, as evaluated by the Charlson Comorbidity Index [29] ), laboratory test results, radiological findings, clinical management, in-hospital complications, length of hospital stay, early readmissions, referral to long-term care or skilled nursing facilities, and deaths. Patients were treated at their attending physician's discretion according to local protocols and their clinical judgment.

The SEMI-COVID-19 Registry was approved by the Provincial Research Ethics Committee of Málaga (Spain). Given that it is observational in nature, the registry poses no additional inconvenience to the patients included. Informed consent was obtained from all patients. When it was not possible to obtain it in writing for biosecurity reasons or because the patient had already been discharged, it was collected verbally and noted on the medical record. More in-depth information and preliminary results of the SEMI-COVID- 19 Registry have recently been published [30] .

We selected all of the patients with ADs included in the registry until 30 June 2020 (prior to the beginning of the vaccination campaign in Spain) and compared them with the remaining patients. The ADs were defined based on the information included in the medical record and the judgment of the physician in charge of entering the data into the registry, which was done using a standardized online data capture system. The primary outcome of the study was all-cause mortality during admission, readmission, and subsequent admissions. Secondary outcomes were a composite outcome, including the need for ICU admission, invasive and non-invasive MV, or death, as well as in-hospital complications. The latter included secondary bacterial pneumonia, acute respiratory distress syndrome (ARDS), acute heart failure, arrhythmia, acute coronary syndrome, myocarditis, seizures, stroke, shock, sepsis, acute kidney failure, disseminated intravascular coagulation (DIC), venous thromboembolism, multiple organ dysfunction syndrome, and acute limb ischemia.

Categorical variables were presented as a number (percentage), and continuous variables were reported as the mean ± standard deviation (SD). Categorical variables were compared using the chi-squared or Fisher's exact tests. Continuous variables were compared using an ANOVA test. The level of significance was established as a two-tailed p < 0.05. No corrections were made for multiple comparisons.

The different models of logistic regression were developed with the group of patients in the registry without ADs who had valid information in all of the predictor and result variables included in the corresponding analysis. For patients with ADs, the missing data were completed by multiple imputations [31] . Multivariable logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (95% CI) when comparing outcomes, mortality, composite outcomes, and complications during hospitalization. The regression model included sociodemographic variables, comorbidities, and prior ISTs. For the predictor variable selection process, the Wald statistic, forward method, was used, with inclusion p < 0.05 and exclusion p < 0.10.

As it is an observational, non-randomized study, to reduce the number of model predictor variables, avoid selection biases, and better control the influence of their possible confounding effect, the different propensity scores (PSs) were independently calculated [32, 33] for the binary variables of ADs, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjögren syndrome (PSS), systemic sclerosis (SSc), mixed connective tissue disease (MCTD)/overlap syndrome, inflammatory myopathies (IM), primary antiphospholipid syndrome (APS), spondyloarthropaties, vasculitis (systemic vasculitis, including giant cell arteritis), polymyalgia rheumatica (PMR), and combined PMR/giant cell arteritis.

In the first step, in the logistic regression model that included the previously cited variables as dependents and variables on sociodemographic data, comorbidity, preadmission ISTs, and drugs received during the hospital stay as predictors, the estimated probability for each dependent variable was calculated as a PS using the enter method. In the next step, this PS was weighted by calculating its inverse (inverse propensity score weighting (IPSW) method) in patients with AD as 1/PS and in patients without AD as 1/(1-PS); the histogram of the weighted scores showed that the groups were comparable. Subsequently, an analysis of generalized estimation equations was carried out in the generalized linear models module of the SPSS statistical package in order to retrieve the original sample sizes and calculate the OR with their 95% CI. To assess the robustness of the results, sensitivity analyses were performed, comparing the results of the logistic regression analysis with those obtained through the IPSW method. All analyses were conducted using IBM SPSS Statistics for Windows, Version 22.0. (Armonk, NY: IBM Corp., US).

As of 30 June 2020, a total of 13,940 patients diagnosed with COVID-19 were included in the SEMI-COVID-19 Registry, of which 362 (2.6%) had ADs, which were sub-classified into classic ADs, other ADs, and miscellaneous ADs (Table 1) . The average age of patients with ADs was somewhat higher, and female sex was more frequent than in the general population. They had greater comorbidity, with a Charlson Index > 2, especially in the group of patients with classic ADs (2.66 vs. 1.27 in the general population). The clinical manifestations, physical examination on admission, and radiological alterations of patients with ADs were similar to the general population (Table 2 and Table S1 ). Patients with ADs were being treated with ISTs more frequently ( Table 2 ). During admission, patients with AD received ISTs more frequently than the general population, especially CS and immunoglobulins (IGIV), while the use of antimalarial drugs, which were part of the standard of care during a certain period of time in Spain, was similar in all groups (Table 3) . 

Although the duration of admission was similar in all groups, in the univariate analysis, patients with ADs had more complications (p = 0.008) and higher mortality (p < 0.001), and met the criteria of the composite outcome more often than the general population (p < 0.001), especially the group of classic ADs and other ADs (Table 4 ). In multivariate logistic regression analysis, the ADs as a whole showed neutral effects on the outcome variables (mortality, composite outcome, and complications). Habitual treatment with CS was associated with a greater risk of these outcome variables, unlike the rest of the habitual ISTs, which had a neutral effect. Age, male sex, Hispanic ethnicity/race, Barthel Index score, and comorbidity (Charlson Comorbidity Index, hypertension, dyslipidemia, obesity, respiratory pathology, non-arteriosclerotic cardiovascular disease, and transplantation) were also poor prognostic factors (Table 5) .

When we analyzed the effect of ADs as a whole and individually, as well as the habitual ISTs on the outcome variables by calculating the IPSW method, ADs as a whole were not associated with higher mortality, increased risk of the composite outcome, or more complications during admission (Table 6 ). Some Ads, such as RA, PMR, and vasculitis, were associated with higher mortality; spondyloarthropathies, vasculitis, and PMR were associated with a higher risk of the composite outcome, as well as RA, with higher risk of complications during hospitalization. SSc was associated with a lower risk of mortality, composite outcome, and complications during hospitalization. Similarly, PSS was associated with fewer complications during hospitalization (Supplementary Table S2 ). The effect of the habitual ISTs was very variable. BDMARDs were associated with a decrease in mortality in the set of Ads, and were especially beneficial in spondyloarthropathies, although contradictory results were observed in SLE, RA, and vasculitis. CS did not affect the overall ADs, but was detrimental in some diseases, such as PSS, SSc, MCTD/overlap, APS, IM, and vasculitis. Cs/tsDMARDs also did not affect the overall group, but were beneficial in some diseases, such as PMR/giant cell arteritis, SLE, and RA. Finally, antimalarials did not change the prognosis. α Propensity scores were obtained with the inverse weighting method. Outcome variables were mortality, composite outcome (mortality, mechanical ventilation, and ICU admission), and complications during the hospitalization. Predictor variables included in the logistic regression model to estimate the propensity score: age, sex, race, form of acquisition (common/nosocomial/residency), alcohol use disorder, smoking, Barthel Index score, comorbidity, Charlson Comorbidity Index, immunosuppressive/immunomodulatory treatments prior to admission (anti-malarial, glucocorticoids, cs/tsDMARDs, bDMARDs) and during hospitalization (antimalarials, tocilizumab, immunoglobulins, anakinra, baricitinib, corticosteroids), and the presence of a complication during hospitalization (38 exposure variables to calculate the propensity scores). A total of 11,174 patients hospitalized by COVID-19 were included. AD: autoimmune disease; bDMARDs: disease modifying anti-rheumatic drugs, original, biologic, or similar; cs/tsDMARDs: disease-modifying anti-rheumatic drugs, synthetic, conventional, or targeted; ICU: intensive care unit.

In this study, we analyzed data from one of the largest cohorts of hospitalized patients with ADs and COVID-19 published to date. In this registry, patients with ADs accounted for 2.6% of the total number of patients admitted to 150 hospitals in Spain for COVID-19. Other authors have described figures that range from ≤ 1% to 10% [34] [35] [36] . This variability could be influenced by the different prevalence of ADs according to the geographical area [37] , as well as the selection and classification criteria of the ADs used. In the nationwide Spanish SEMI-COVID-19 Registry, several ADs were included based on the dysfunction of the underlying immune system, the possibility of receiving ISTs, and the judgment of the clinician in charge of data entry, which were gathered from the information contained in the medical record. The actual incidence of COVID-19 in patients with ADs is still unknown. Worldwide, in different epidemiological contexts and for different ADs, its incidence has been described as being both similar [10, [12] [13] [14] 38, 39] and higher [6, 7, 40] than among the general population. In our case, the design of the registry does not allow for an approximation in this regard beyond what has been observed in hospitalized patients in our country.

In this registry, patients with ADs were more frequently female, older, more dependent, and with greater comorbidity than patients without ADs. In the univariate analysis, patients with ADs had higher mortality, met the criteria of the composite outcome more often, and had more complications during hospitalization. However, after controlling for the effect of possible known confounding factors using multivariate logistic regression and the IPSW method, the presence of an ADs did not entail a greater risk of these variables.

Two international registries of patients with ADs and a recent meta-analysis have shown the deleterious effect of age and comorbidity on the prognosis of COVID-19 [8, [41] [42] [43] . These same factors may have acted as confounders of the higher mortality, composite outcome, and complications that we observed in the univariate analysis in patients with ADs. In the multivariate analysis, in which the effect of ADs on the prognosis of COVID-19 was estimated, taking into account these and other confounding factors (age, sex, ethnicity/race, comorbidities, alcohol and tobacco use, degree of dependency, and ISTs before and during admission), no relationship with the prognosis was observed. Age, male sex, and comorbidity behaved as poor prognostic factors in patients with ADs, as well as in the general population. Different studies published around the world support the idea that patients with ADs and COVID-19 have a similar clinical course to that of the general population [6, 12, 13, 17, 34, 35, 44, 45] . Only two cohorts, both of which included only a small number of patients with ADs, found a higher frequency of respiratory failure [46] and need for MV or ICU admission [9] in patients with ADs compared to the general population, although there were no differences in the mortality rates in both cases.

Few studies have assessed the effect of different ADs on the prognosis of COVID-19. In our study, analyzed individually, worse progress was observed in patients with certain ADs, including RA, PMR, vasculitis, and spondyloarthropathies, and better progress in others, such as PSS and SSc (Table S2 ). Other authors have found a greater risk of severe COVID-19 in patients with systemic vasculitis, SLE, PSS, and APS, but they did not find differences between the control group and the group of patients with chronic inflammatory arthritis [47] . Although, in general, having an AD does not necessarily imply a worse prognosis, it cannot be ruled out that specific diseases with different pathogenic mechanisms and phenotypic characteristics would entail a different clinical course than the rest. Until now, the small number of patients with specific diseases that have been included in the publications, the absence of a control group, and the lack of control of biases and confounding factors have not allowed for the effects of these diseases to be fully characterized. Further analysis would be needed to evaluate the severity of specific conditions within the heterogeneous AD group.

Another concern during the pandemic has been the impact of basal ISTs (CS, antimalarials, and DMARDs) on the prognosis of COVID-19. The onset of hyper-inflammatory syndromes and even immune reconstitution inflammatory syndrome associated with poor prognosis have been described in the course of SARS-CoV-2 infection [48] . Immunosuppressive therapies have been used for the treatment of this inflammatory phase of the disease [24, 49] , similar to other ADs associated with viral infections (such as cryoglobulinemia and hepatitis C virus or polyarteritis nodosa and hepatitis B virus [50] ). In addition, ensuring that ADs remain in remission helps prevent infections in general [51] or the least poor progression of them [52] . In this context, various authors have suggested that basal ISTs would not result in a more severe clinical course [45] , and could even have some protective effect [14, 15, 21, 49] . In this study's multivariate logistic regression analysis, the habitual treatment with CS was associated with higher mortality among patients with ADs. In the analysis, by calculating the PS, habitual CS did not influence the prognosis of ADs as a whole, although we did find a significant influence in a few diseases. Two large registries of patients with ADs and a recent meta-analysis have also shown the deleterious effect of CS on the prognosis of COVID-19 [8, [41] [42] [43] . No information was collected in this registry on the dose or duration of pre-admission CS treatment or the activity of the underlying disease, which may have influenced these results.

Regular treatment with antimalarials did not have any protective effect, which is consistent with the results of other observational studies in patients with ADs [9, 12, 23, 41] . However, in patients with PMR, antimalarials were associated with more complications, although the 95% CI was quite wide, and thus was too imprecise to be taken into consideration.

In our study, the regular use of DMARDs (bDMARDs or cs/tsDMARDs) tended to have a neutral or protective effect against the outcome variables in the whole of the ADs and in specific diseases. Other authors have also found a neutral [6, 16, 38, 42, 47, 53] or protective [41] effect of bDMARDs and cs/tsDMARDs [41, 47, 53] . Better control of disease activity, as well as the attenuation or prevention of an excessive inflammatory response to COVID-19, could explain the protective or neutral effect of these drugs. In the case of SLE and RA, however, bDMARDs were shown to be harmful. A lack of information about other possible confounding factors, such as AD activity, may have influenced this result.

One of the main strengths of our study is the large number of patients included from the internal medicine departments of more than 150 hospitals. Furthermore, data were collected using a standardized, previously agreed upon protocol. Multiple imputations of the missing data, both randomized and biased, were performed on patients with ADs, which allowed all of them to be analyzed. To avoid selection biases and control for confounding factors in the estimation of the effect of ADs, a multivariate analysis was carried out, and the PS was estimated using the IPSW method. Finally, as a sensitivity analysis, the results obtained in the previous analyses were compared.

Our study has some limitations. In addition to being retrospective, the registry was not specifically designed to evaluate the effect of ADs, but rather was designed as a general registry of patients hospitalized due to COVID-19. This registry took advantage of the information available in electronic medical records, but the data were collected by a large number of researchers from different centers who were not necessarily specialized in ADs or in charge of patient care. This could have led to heterogeneity in the collection and validation of this information. Patients who were unable to provide informed consent at any time, either because of severe illness or mechanical ventilation, were excluded. However, they represent an extremely small proportion of patients, and thus have little impact on the results. The group of patients classified as having ADs included patients with various diseases. Their inclusion in this group was based on the baseline dysfunction of the immune system, the possibility of receiving immunosuppressive treatment, and the judgment of the physician in charge of entering the data, which reflects the habitual clinical practice and allowed us to increase the sample size. Since it was a very heterogeneous group, a subgroup analysis (classical, other, and miscellaneous) and analyses of specific entities were also performed. In the analysis, general population cases that were missing data for any of the variables of the different statistical analyses carried out were excluded from the control group, but, given the large sample size, the power of the statistical contrasts was not affected. On the other hand, the effect of the AD activity or the antiviral or antimicrobial drugs used during hospitalization were not evaluated, although some of the latter have not been proven effective in other studies [54] . In order to create the multivariate statistical contrast models, the admission date was not included. This may entail a selection bias, since, although little time has passed since the beginning of the pandemic, the management of patients may have changed in these months.

In conclusion, this analysis of the SEMI-COVID-19 Registry found that ADs do not entail a different prognosis, as measured by mortality, the composite outcome (mortality/ICU admission/need for MV), or complications, than that of the rest of patients hospitalized due to COVID-19 in Spain. Considered individually, it cannot be ruled out that some diseases entail a better or worse prognosis than the general patient population. The use of ISTs before admission had variable effects.

More studies are needed, including outpatient cohort studies, in order to determine the different aspects that affect COVID-19 prognosis in patients with ADs.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/jcm10091844/s1. Table S1 . Baseline characteristics among groups; Table S2 . Measures of the effect, OR (95% CI), of ADs individually and immunomodulatory treatments prior to hospital admission with their propensity scores as the outcome variables. 

Lina Marcela Parra Ramírez, Ilduara Pintos Pascual

Uxua Asín Samper, María Aranzazu Caudevilla Martínez

Yaiza García del Álamo Hernández

Hospital Clínico de Santiago. Santiago de Compostela Maria del Carmen Beceiro Abad

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study

Risk of severe herpes simplex virus infection in systemic lupus erythematosus: Analysis of epidemiology and risk factors analysis in Taiwan

Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration

RIER investigators group. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US 'hot spot

SARS-CoV-2 infection among patients with systemic autoimmune diseases

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: What can we learn from observational data?

Peyrin-Biroulet, L. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California

Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19

Covid-19 in Immune-Mediated Inflammatory Diseases-Case Series from New York

Rheumatic diseases in intensive care unit patients with COVID-19

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey

SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis

Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients?

Interferon alpha as a primary pathogenic factor in human lupus

Mortality prediction in systemic lupus erythematosus patients with pulmonary infection

Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients

Functional evaluation: The Barthel Index

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

SEMI-COVID-19 Network. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Network

Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls

Analysis of causality from observational studies and its application in clinical research in Intensive Care Medicine

A review of propensity-score methods and their use in cardiovascular research

Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: A retrospective study

Brescia Rheumatology COVID-19 Study Group. COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study

Determinants of COVID-19 disease severity in patients with underlying rheumatic disease

Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases

Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine

Rheumatic disease and COVID-19: Initial data from the COVID-19 Global Rheumatology Alliance provider registries

Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry

but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: The Northern Italy experience

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Clinical features of rheumatic patients infected with COVID-19 in Wuhan

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study

Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: Case-control study

COVID-19: The new challenge for rheumatologists

Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence? Mediterr

Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis

Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study

Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study

A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19

The authors declare no conflict of interest.

The data this study is based on are available from the corresponding author upon reasonable request.